Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › BCRX

RICE HALL JAMES & ASSOCIATES, LLC position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 2,268,561 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$18.9M, representing 1.00% of its reported portfolio and ranking #33 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed BCRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)2.27M sh
Reported value held$18.90M
Portfolio Weight1.00%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's BCRX position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in BCRX in Q3 2023 at 2,275,638 shares (US$16.1M). The position peaked in Q2 2026 at 2,332,043 shares, worth US$23.3M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,268,561 shares valued at US$18.9M — a reduction of -63,482 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.28M $16.11M New
Q4 2023 2.20M $13.16M Reduce
Q1 2024 2.15M $10.93M Reduce
Q2 2024 2.08M $12.85M Reduce
Q3 2024 2.16M $16.44M Add
Q4 2024 2.08M $15.65M Reduce
Q1 2025 2.03M $15.21M Reduce
Q2 2025 2.06M $18.46M Add
Q3 2025 1.88M $14.27M Reduce
Q4 2025 1.90M $14.85M Add
Q1 2026 2.23M $21.23M Add
Q2 2026 2.33M $23.32M Add
Q3 2026 2.27M $18.90M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), PERCEPTIVE ADVISORS LLC (US$103.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held BCRX?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed BCRX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in BCRX?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 2.27M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $18.90M, representing 1.00% of its reported portfolio and ranking #33.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling BCRX?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in BCRX. The position peaked in Q2 2026 at 2.33M shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., PERCEPTIVE ADVISORS LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.